Plerixafor Injection
Brand names: Plerixafor
Category: Hematology
FDA status: To Be Discontinued · Last FDA update: Mar 13, 2026 · First posted: Mar 13, 2026 · 1 manufacturers, 1 listed presentations
As of Mar 13, 2026, the FDA lists Plerixafor Injection as being discontinued. Of 1 manufacturer presentations, 1 Not specified.
| Presentation & package NDC | Manufacturer | Availability | FDA note |
|---|---|---|---|
| Plerixafor, Injection, 24 mg per 1.2 mL (20 mg per mL) (NDC 65219-284-12) NDC 65219-284-12 |
Fresenius Kabi USA, LLC | Not specified | A business decision was made to discontinue manufacture of the drug. |
Related medications in shortage
Other Hematology medications currently on the FDA shortage list — useful context if you and your prescriber are weighing alternatives. Always confirm with your pharmacist.
Change log
Tracking began Oct 1, 2026. We check the FDA every 6 hours; any real change - a manufacturer moving from Limited to Available, a new recovery date, a new listing - shows up here with its date.
Cite this: “FDA drug-shortage status for Plerixafor Injection (FDA data as of Mar 13, 2026). Shortage Watch, openFDA.”
Get an email when this record changes
One email, only when the FDA changes something for Plerixafor Injection. You confirm by clicking a link first (double opt-in). No newsletter, no other mail.
Feeds instead of email: RSS or JSON. Unsubscribe anytime; see Privacy.
Embed a live status badge: /badge/plerixafor-injection.svg
FDA data last synced Oct 1, 2026 (FDA record dated Sep 30, 2026).